Compare Roundhill Russell 2000 0DTE Covered Call Strat ETF (RDTE) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill Russell 2000 0DTE Covered Call Strat ETF vs Repligen Corporation Common Stock — how do they compare? Roundhill Russell 2000 0DTE Covered Call Strat ETF trades at $25.29 (market cap $159.50M), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 69.8× Roundhill Russell 2000 0DTE Covered Call Strat ETF's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Roundhill Russell 2000 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Roundhill Russell 2000 0DTE Covered Call Strat ETF for 56 Days and Repligen Corporation Common Stock for 0 Days on average.
| RDTE | RGEN | |
|---|---|---|
Market Cap | $159.50M | $11.14B |
Volume | 55,754 | 1,259,263 |
Sector | Income / Options Overlay | Health |
52-Week High | $33.66 | $194.57 |
52-Week Low | $25.43 | $102.87 |
Typical Hold Time | 56 Days | 0 Days |
Enterprise Value | — | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RDTE (Roundhill Russell 2000 0DTE Covered Call Strategy ETF) trades at $25.91, down 0.54% with bearish technical indicators showing 17 sell signals versus 0 buy signals. The ETF faces capital erosion concerns despite offering high dividend yields through its covered call strategy on Russell 2000 small-cap stocks. Recent dividend payments have ranged from $0.10 to $0.23 per share, but the fund's income generation comes with significant price depreciation risk.
The outlook remains challenging as technical analysis indicates strong bearish momentum with moving averages unanimously signaling sell. Fundamental data is limited but the covered call strategy exposes investors to capped upside potential during market rallies while providing limited downside protection. Key risks include small-cap volatility and the structural limitations of 0DTE options strategies in generating sustainable income.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roundhill Russell 2000 0DTE Covered Call Strat ETF
RDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the Russell 2000 Index. The fund primarily holds a portfolio of short-term U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the Russell 2000. This highly tactical strategy aims to maximize premium capture by exploiting the high time decay of options that are expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on RDTE →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
